This site is intended for U.S. Healthcare Professionals only.

Clinical data—cUTI,
including pyelonephritis

  • The determination of efficacy of AVYCAZ in cUTI is supported in part by the previous findings of the efficacy and safety of ceftazidime for the treatment of cUTI1
  • In cUTI, the contribution of avibactam to AVYCAZ has been established in vitro and in animal models of infection1
    • Avibactam restored activity of ceftazidime in animal models of infection (eg, pyelonephritis) caused by ceftazidime-nonsusceptible β-lactamase-producing (eg, ESBL, KPC, and AmpC) Gram-negative bacteria1
  • AVYCAZ was studied in a Phase 2 randomized, blinded, active-controlled, multicenter trial in cUTI, including pyelonephritis1
    • This trial was not designed with any formal hypotheses for inferential testing against the active comparators1

ESBL, extended-spectrum β-lactamase. KPC, Klebsiella pneumoniae carbapenemase.